Follow us on LinkedIn
Latest News
A cost-effective combined advanced therapy to treat knee osteoarthritis

About us

Osteoarthritis (OA) affects 500 million people in Europe. Available therapies are associated with moderate efficacy and long-term side effects.

The vision of the international team of the EU research project SINPAIN is to improve the quality of life for those affected by OA and reduce the substantial costs linked with the disease by developing a new generation of OA therapeutics. To achieve this, SINPAIN is developing an innovative nanotherapeutics pipeline based on siRNA for treating different stages of knee OA.

Overall, the envisioned therapeutics could alleviate the pain of knee osteoarthritis patients worldwide.

Watch the SINPAIN video to learn more
01 May 2022 start date
54 months of duration
EUR 5.3 Mil Budget
12 partners from 9 countries

Understanding Osteoarthritis

Osteoarthritis (OA) ranks among the most common joint disorders worldwide affecting more than 500 million patients across the globe. In Western Europe, more than 57 million people suffer from OA. Long considered a “wear and tear” condition of the elderly, it is now known that OA is a highly complex disease of the entire joint affecting a large proportion of the population under the age of 65.

Typically developing over time as a chronic disease, OA involves all tissues of the joint including the bone, ligaments, cartilage, fat, and the tissues lining the joint. While any joint of the body can be affected, it is most frequently caused in the knee, hand, and hip.

Read more